A systematic review of intracranial chondrosarcoma and survival

Abstract

Most data regarding survival in patients with chondrosarcoma are limited to case studies and small series performed at single institutions. A systematic review was performed to study the relationship between potential prognostic factors and survival. The survival rates were analyzed according to modality of treatment, treatment history, histological subtype, and histological grade. A total of 560 patients with intracranial chondrosarcoma were analyzed. Median follow-up time was 60 months. The 5-year mortality among all patients was 11.5% with median survival of 24 months. Mortality at 5 years was significantly greater for patients with tumors of higher grade, or of the mesenchymal subtype, or who had received surgical resection alone. The results of our systematic review provide useful data in predicting survival among intracranial chondrosarcoma patients.

Figures

Fig. 1

The effect of treatment on the 5-year mortality rate from chondrosarcoma showing that mortality was higher in patients who had undergone surgery only.

Fig. 2

The effect of previous treatment on the 5-year mortality rate from chondrosarcoma showing that treatment history had no effect.

Fig. 3

The effect of histological subtype on the 5-year mortality rate showing that mortality was lower among patients with the conventional chondrosarcoma subtype.

Fig. 4

The effect of histological grade on the 5-year mortality rate showing that mortality increased with a corresponding increase in World Health Organization grade (I–III) chondrosarcoma.